CHRO רווח למניה בשנים עשר החודשים האחרונים Chromocell Therapeutics Corporation

The development of non-opioid analgesics is hindered by strict FDA control over molecular toxicity. The annual net income per share trend on this GURU.Markets platform chart shows that the value of -1.74 corresponds to the current metric. Chromocell Therapeutics (CHRO) maintains scientific authority in the study of sodium channels, which attracts physicians, while its ownership of patents for selective inhibitors ensures a steady stream of free cash flow.

This metric is calculated by dividing the total annual net income by the total number of shares outstanding. The metric reflects the actual income per share, allowing for an assessment of business efficiency regardless of the issuance volume. For Chromocell Therapeutics (CHRO), this calculation demonstrates the financial return from the operation of the Chromovert platform and B2B contracts. By analyzing the fundamental net income per share TTM metric, an investor determines the long-term capitalization potential. This chart's dynamics reveal the resilience of the company's patent perimeter.